Evidence map›Paper›PMID 41744975›Full record

ArticleGels (Basel, Switzerland)2026

Structural, Swelling, and In Vitro Digestion Behavior of DEGDA-Crosslinked Semi-IPN Dextran/Inulin Hydrogels.

Tamara Erceg, Miloš Radosavljević, Ružica Tomičić, Vladimir Pavlović, Milorad Miljić, Aleksandra Cvetanović Kljakić, Aleksandra Torbica

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tamara ErcegFaculty of Technology Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0002-9765-8882
Miloš RadosavljevićFaculty of Technology Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0001-6473-5282
Ružica TomičićFaculty of Technology Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0002-5602-8761
Vladimir PavlovićFaculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Belgrade, Serbia.
Milorad MiljićInstitute of Food Technology in Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0002-9278-9330
Aleksandra Cvetanović KljakićFaculty of Technology Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0001-5621-1788
Aleksandra TorbicaInstitute of Food Technology in Novi Sad, University of Novi Sad, Bulevar Cara Lazara 1, 21000 Novi Sad, Serbia.ORCID 0000-0002-9627-1598

Funding

project Interreg, co-founded by the European Union, " Targeted delivery of antitumor drugs employing biodegradable carriers ABIDERS HR-RS00148 00148
6 · The paper itself

Abstract

In this study, semi-interpenetrating polymer network (semi-IPN) hydrogels based on methacrylated dextran and native inulin were designed as biodegradable carriers for the colon-specific delivery of uracil as a model antitumor compound. The hydrogels were synthesized via free-radical polymerization, using diethylene glycol diacrylate (DEGDA) as a crosslinking agent at varying concentrations (5, 7.5, and 10 wt%), and their structural, thermal, and biological properties were systematically evaluated. Fourier transform infrared spectroscopy (FTIR) confirmed successful crosslinking and physical incorporation of uracil through hydrogen bonding. Concurrently, differential scanning calorimetry (DSC) revealed an increase in glass transition temperature (

Indexed as

biodegradation in intestinal fluiddextraninulinsemi-interpenetrating biopolymer hydrogel

Identifiers

PMID41744975
PMCPMC12941329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.